Patents by Inventor Peter WESSELS
Peter WESSELS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11925890Abstract: Aspects herein include monitoring devices for filtration systems. An embodiment of the monitoring device can include a first fluid conduit and a first pressure sensor, wherein the first pressure sensor is in fluid communication with the first fluid conduit. The monitoring device can also include a second fluid conduit and a second pressure sensor, wherein the second pressure sensor is in fluid communication with the second fluid conduit. The monitoring device can also include a control circuit in electronic communication with the first pressure sensor and the second pressure sensor. The monitoring device can also include a housing, wherein the first pressure sensor, the second pressure sensor and the control circuit are all disposed within the housing. Other embodiments are also included herein.Type: GrantFiled: October 23, 2019Date of Patent: March 12, 2024Assignee: Donaldson Company, Inc.Inventors: Wade A. Wessels, Peter P. Vitko, Brent R. Nelson
-
Patent number: 10722466Abstract: The invention relates to a pharmaceutical liposomal composition comprising 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno [2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl) propanoic acid, referred to herein as ‘Compound A’, or a pharmaceutically acceptable salt thereof. More specifically the invention relates to a liposomal vehicle, an organic concentrate composition comprising Compound A, and a pharmaceutical composition for parenteral administration comprising liposomes and Compound A. Furthermore, the invention relates to the use of such compositions for the treatment of cancer. ‘Compound A’ as used herein includes all enantiomers, diastereoisomers, and atropisomers thereof, or mixtures thereof, and also optionally includes the pharmaceutically acceptable salts thereof.Type: GrantFiled: October 27, 2017Date of Patent: July 28, 2020Assignees: LES LABORATOIRES SERVIER, NOVARTIS AGInventors: Peter Wessels, Henricus Tiemessen, Paolo De Marco, Malika Larabi, Christiane Schiedel, Marina Gurina
-
Publication number: 20200054557Abstract: The invention relates to a pharmaceutical liposomal composition comprising 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno [2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl) propanoic acid, referred to herein as ‘Compound A’, or a pharmaceutically acceptable salt thereof. More specifically the invention relates to a liposomal vehicle, an organic concentrate composition comprising Compound A, and a pharmaceutical composition for parenteral administration comprising liposomes and Compound A. Furthermore, the invention relates to the use of such compositions for the treatment of cancer. ‘Compound A’ as used herein includes all enantiomers, diastereoisomers, and atropisomers thereof, or mixtures thereof, and also optionally includes the pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 27, 2017Publication date: February 20, 2020Inventors: Peter WESSELS, Henricus TIEMESSEN, Paolo DE MARCO, Malika LARABI, Christiane SCHIEDEL, Marina GURINA
-
Patent number: 9034179Abstract: A method and device for the cleaning of spiral wound membranes. In the device two or more spiral wound membranes are included in series in pressure tubes. The membranes are cleaned by longitudinal rinsing with water, in which a well-dissolvable gas has been dissolved. In the device for the purification of an aqueous fluid with spiral wound membranes, the membranes can be longitudinal rinsed with water, in which a well-dissolvable gas has been dissolved. As gas that is well-dissolvable preferably CO2 gas or a mixture of gasses is used.Type: GrantFiled: February 10, 2010Date of Patent: May 19, 2015Assignees: WE CONSULT VIANEN B.V., VITENS N.V.Inventors: Leo Peter Wessels, Walterus Gijsbertus Joseph Van Der Meer
-
Patent number: 8163778Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.Type: GrantFiled: November 24, 2008Date of Patent: April 24, 2012Assignee: Hoffmann-LA Roche Inc.Inventors: Wolfgang Haap, Paul Hebeisen, Eric Argirios Kitas, Bernd Kuhn, Peter Mohr, Hans Peter Wessel
-
Patent number: 7973051Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.Type: GrantFiled: November 10, 2008Date of Patent: July 5, 2011Assignee: Hoffman-La Roche Inc.Inventors: Paul Hebeisen, Eric A. Kitas, Rudolf E. Minder, Peter Mohr, Hans Peter Wessel
-
Patent number: 7803819Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: July 17, 2007Date of Patent: September 28, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
-
Publication number: 20100222340Abstract: The present invention relates to compounds of formula (I) wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: ApplicationFiled: May 13, 2010Publication date: September 2, 2010Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Fabienne Ricklin, Hans Peter Wessel
-
Publication number: 20100200504Abstract: A method and device for the cleaning of spiral wound membranes. In the device two or more spiral wound membranes are included in series in pressure tubes. The membranes are cleaned by longitudinal rinsing with water, in which a well-dissolvable gas has been dissolved. In the device for the purification of an aqueous fluid with spiral wound membranes, the membranes can be longitudinal rinsed with water, in which a well-dissolvable gas has been dissolved. As gas that is well-dissolvable preferably CO2 gas or a mixture of gasses is used.Type: ApplicationFiled: February 10, 2010Publication date: August 12, 2010Applicants: WE Consult Vianen B.V., Vitens N.V.Inventors: Leo Peter Wessels, Walterus Gijsbertus Joseph Van Der Meer
-
Patent number: 7718666Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: June 17, 2004Date of Patent: May 18, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Bernd Kuhn, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Hans Peter Wessel
-
Publication number: 20090143439Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.Type: ApplicationFiled: November 24, 2008Publication date: June 4, 2009Inventors: Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Peter Mohr, Hans Peter Wessel
-
Publication number: 20090143448Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.Type: ApplicationFiled: November 10, 2008Publication date: June 4, 2009Inventors: Paul Hebeisen, Eric A. Kitas, Rudolf E. Minder, Peter Mohr, Hans Peter Wessel
-
Patent number: 7314884Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: December 13, 2004Date of Patent: January 1, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
-
Publication number: 20070259925Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: ApplicationFiled: July 17, 2007Publication date: November 8, 2007Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Loeffler, Ramakanth Sarabu, Hans Peter Wessel
-
Patent number: 7189756Abstract: The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.Type: GrantFiled: June 30, 2004Date of Patent: March 13, 2007Assignee: Hoffman-La Roche Inc.Inventors: Johannes Aebi, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Ulrike Obst, Hans Peter Wessel
-
Patent number: 7071212Abstract: The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: wherein R1, E, X1 to X4 and G1 and G2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.Type: GrantFiled: August 12, 2003Date of Patent: July 4, 2006Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, Leo Alig, Alexander Chucholowski, Katrin Groebke, Kurt Hilpert, Holger Kuehne, Ulrike Obst, Lutz Weber, Hans Peter Wessel
-
Patent number: 6861440Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.Type: GrantFiled: October 14, 2002Date of Patent: March 1, 2005Assignee: Hoffmann-La Roche Inc.Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
-
Publication number: 20040259902Abstract: The present invention relates to compounds of formula (I) 1Type: ApplicationFiled: June 17, 2004Publication date: December 23, 2004Inventors: Markus Boehringer, Bernd Kuhn, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Hans Peter Wessel
-
Publication number: 20040242672Abstract: The present invention relates to pyrrolidine derivatives useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in treating disease states associated with vasoconstriction.Type: ApplicationFiled: June 30, 2004Publication date: December 2, 2004Inventors: Johannes Aebi, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Ulrike Obst, Hans Peter Wessel
-
Publication number: 20040226872Abstract: An apparatus for purifying water, comprising an ion exchanger with a water inlet and a product outlet, connected to an inlet of a first filtration step, which comprises one or more nano- and/or RO-filtration membranes and is provided with a first permeate outlet and a first concentrate outlet. According to a first embodiment, the apparatus comprises a subsequent filtration step in which an inlet is connected with the first concentrate outlet, which subsequent filtration step comprises one or several subsequent nano- and/or RO-filtration membranes, and which is provided with a second permeate outlet and second concentrate outlet, which second concentrate outlet is optionally connected with an inlet of a subsequent filtration step.Type: ApplicationFiled: January 9, 2004Publication date: November 18, 2004Applicants: DHV Water B.V., Vitens FrieslandInventors: Leo Peter Wessels, Michel Riemersma, Walterus Gijsbertus Joseph Van der Meer